

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascletis Pharma Inc.

歌禮製藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1672)

CLARIFICATION ANNOUNCEMENT

FORM OF PROXY FOR THE 2020 ANNUAL GENERAL MEETING

References are made to the notice (the “**AGM Notice**”) of the annual general meeting to be held on June 15, 2020 (the “**AGM**”) and the form of proxy for the AGM (the “**Form of Proxy**”) published on May 13, 2020 by Ascletis Pharma Inc. (the “**Company**”).

The Company would like to make clarification to resolution numbered 2 ii) on the English version of the Form of Proxy as follows:

2 ii) To re-elect Ms. Lin HUA as a Director.

Save as above, all other information stated in the AGM Notice and the Form of Proxy remains unchanged. This clarification announcement is supplemental to and should be read in conjunction with the AGM Notice and the Form of Proxy. The Form of Proxy which has been dispatched for the purpose of the AGM will remain valid for use for the AGM.

By order of the Board
Ascletis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People’s Republic of China
May 28, 2020

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; Dr. Ru Rong JI, Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.